The European Union’s groundbreaking Biotech Act, intended to accelerate the innovation pipeline for life sciences, is facing significant criticism from the food industry over its exclusion of novel foods from designated regulatory sandboxes. This decision, announced in December, has ignited a firestorm of protest from a coalition of eight influential food and biotechnology organizations, including FoodDrinkEurope, which represents some of the continent’s largest food corporations. Industry leaders argue that this exclusion is not only illogical but actively counterproductive to the very goals the Biotech Act aims to achieve.
At the heart of the controversy lies the definition of regulatory sandboxes: controlled environments designed to foster collaboration between businesses, researchers, and regulators. These sandboxes allow for the iterative development and refinement of standards and guidance for novel products before they undergo formal approval processes. While the Biotech Act establishes these sandboxes for a range of innovations, including food enzymes, additives, production processes, and AI methodologies, it explicitly bars "novel foods" – a category encompassing products like cultivated meat and precision-fermented proteins – from participating.
The stated rationale within the Act for this exclusion is rooted in the acknowledgement that "Experience has shown that certain types of novel foods trigger ethical or cultural concerns among various consumer segments regarding their acceptability." However, the industry coalition vehemently disputes this justification, asserting in a joint statement that it "does not align with the legal framework of EU food law, where authorisation is based on scientific safety assessment." This discrepancy, they argue, creates an "internal inconsistency within the Biotech Act framework."
A Timeline of Innovation and Regulation
The development of the EU’s Biotech Act is part of a broader strategy to bolster the continent’s life sciences sector, announced in July. The overarching aim was to streamline regulatory pathways, which have historically been a significant bottleneck for emerging food technologies, particularly in the alternative protein space. The initial intention was to enhance pre-submission interactions between regulators and applicants, offering more comprehensive advice to improve the quality of submitted dossiers and expedite approvals from the European Food Safety Authority (EFSA).
However, the final legislative proposal, while aiming to improve dialogue and data submission, inadvertently created a paradox by barring novel foods from the very sandboxes designed to foster innovation in areas directly impacted by biotechnological advancements. This decision was made despite the fact that the novel food framework is the primary regulatory avenue for approving many of these groundbreaking ingredients. By excluding this vital sector, the industry contends, the EU is "remov[ing] the possibility for the EU food sector to test and refine many of the very innovations that the Biotech Act seeks to promote."
Incoherence in the Regulatory Framework
The industry groups highlight a fundamental "incoherence" in the Biotech Act’s approach. They point out that the proposed sandboxes are permitted to cover aspects like food enzymes, additives, flavourings, production processes, and AI methodologies, provided they do not result in a product classified as a novel food. This creates a scenario where the same biotechnological process, data generation method, or AI-supported testing strategy could benefit from a sandbox if applied to an enzyme or processing aid, but would be excluded if it leads to a novel food product.
"This distinction is not based on scientific risk, nor on the nature or complexity of the technology involved, but solely on the regulatory classification of the final product," the joint statement elaborates. "This exclusion weakens the coherence of the regulatory framework and introduces avoidable fragmentation in the treatment of biotechnology-derived innovations." This artificial segmentation, they argue, undermines the very purpose of fostering a cohesive and efficient regulatory environment for biotechnology.
The Value of Regulatory Sandboxes
The participating organizations underscore the critical role regulatory sandboxes play in de-risking innovation. These controlled environments offer a structured and transparent platform for early engagement between innovators and regulatory bodies. Such dialogue is crucial for:
- Clarifying Data Requirements: Ensuring applicants understand precisely what data is needed for a robust safety assessment from the outset.
- Facilitating High-Quality Risk Assessments: Allowing for the refinement of methodologies and data before formal submission, leading to more comprehensive and scientifically sound evaluations.
- Reducing Uncertainty and Costs: Minimizing the risk of costly rejections or lengthy delays due to unforeseen regulatory hurdles.
- Preventing Avoidable Failures: Providing a safe space to identify and address potential issues early in the development cycle.
Global Precedents and the EU’s Competitive Stance
The effectiveness of regulatory sandboxes in driving novel food innovation is already being demonstrated in other major markets. The United Kingdom, for instance, launched a cultivated meat regulatory sandbox in February 2025. This initiative has already yielded significant progress, including the publication of the first set of safety guidance for novel food approvals in the UK. The UK aims to green-light cultivated meat products by next year, a timeline that highlights the potential for well-designed regulatory frameworks to accelerate market entry.
The industry coalition argues that the EU’s exclusion of novel foods, based on broad references to "ethical and cultural concerns," is disproportionate. They note that the vast majority of currently authorized novel food products do not trigger such widespread societal unease. Furthermore, they contend that even in instances where broader societal questions arise, regulatory sandboxes are not intended for market authorization or public debate, but rather for the "scientific and technical preparation of risk assessment." Including novel foods would therefore not compromise the legal basis for authorization, bypass safety assessments, or endanger consumer safety.
Broader Implications for EU Innovation
The exclusion of novel foods from regulatory sandboxes sits uneasily with the broader objectives of the EU’s Biotech Act. The Act is designed to bolster biomanufacturing, promote digitalization, and expand the scope of EFSA’s pre-submission advice. However, by excluding the very category of foods that most directly benefit from these biotechnological advances, the EU is inadvertently hindering its own stated goals.
"The category of foods most directly resulting from these biotechnological advances is excluded from the very instrument designed to support regulatory adaptation to them," the groups lament. They believe that integrating novel foods into the sandbox framework would lead to several positive outcomes:
- Enhanced Safety Assessments: Improving the quality and robustness of scientific evaluations.
- Strengthened EFSA Dialogue: Fostering more effective pre-submission communication between innovators and the authority.
- Validated Methodologies: Supporting the development and validation of novel scientific approaches.
- Evolved Regulatory System: Ensuring that the EU’s regulatory landscape keeps pace with scientific and technological progress in the food sector.
The joint statement represents a united front from a significant portion of the European food and biotech industry, including behemoths like Nestlé, Coca-Cola, ADM, Mars, Danone, Ferrero, and Kraft Heinz. Other signatories include Food Fermentation Europe, EuropaBio, the European Federation of Associations of Health Products Manufacturers, Food Supplements Europe, the European Agrifood Biotech Alliance, and EIT Food. The inclusion of the latter two, which are co-funded by the EU, underscores the internal inconsistencies perceived within the current regulatory strategy.
As the EU navigates the complex landscape of fostering innovation while ensuring consumer safety, this exclusion presents a critical juncture. The industry’s call for a more coherent and inclusive approach to regulatory sandboxes for novel foods suggests that the Biotech Act, while well-intentioned, requires recalibration to truly unlock the potential of the European biotechnology sector and secure its competitive edge in the global food market. The coming months will likely see continued pressure on EU policymakers to address this perceived disconnect and ensure that the regulatory framework truly supports, rather than hinders, the future of food.